CILA Therapeutics has developed a proprietary, first-in-class dry-powder-inhaled (DPI) therapy (CIL-05) for the treatment of Primary Ciliary Dyskinesia.
CIL-05 contains low density respirable microspheres that stabilize the therapeutic activity of otherwise unstable molecules enhancing their efficacy and enabling delivery by a pocket size capsule-based dry-powder-inhaler (DPI) device.
.png)
